An observational study in Female Infertility, sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2024-07-25.
Sponsored by University Hospital, Tours · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Infertility, Female with a site in France — 5 open to participants now, 5 under way, 1 of them phase 3. Infertility, Female · France.
Among the 20 studies in Infertility, Female with a site in France, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2021, is one of 11 observational ones, and was the 10th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →5 of the 20 studies in Infertility, Female with a site in France are open now. Recruiting first, the newest first:
University Hospital, Brest · Sites in France
Ages 25–38 · Women only
Hopital Foch · Sites in France
Ages 18–36 · Women only
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–35 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 43 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 500 is above the median of 160 across 163 observational studies indexed under Infertility, Female.
Median enrollment 237 across the 9 interventional studies, 127 across the 11 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 1 study filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
1 of the studies in Infertility, Female with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04866329University Hospital, ToursFemale Fertility, Environmental Agents and Stress Oxidant | 2026-12-08 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Infertility, Female with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Synthetic products used in industrial, pharmaceutical, agro-alimentary or agricultural fields are found in our environment. Thus, humans could be simultaneously exposed to several of these pollutants. Furthermore, these environmental agents exert or could exert adverse actions on fertility, by altering gamete and embryo quality through endocrine disruptor effects or through increase in oxidative stress in gonads (cellular pathway known to be involved in several human reproductive pathologies).
In this context, the objectives of the present project are to obtain descriptive and analytical data on woman and oocyte exposure to several environmental agents (bisphenols, ethynylestradiol and glyphosate). The relation between these pollutant measures in follicular fluid and urine (from women receiving follow-up of in vitro fertilization (IVF) protocol in the University hospital of Tours, France) and the oocyte quality, the IVF and pregnancy successes will be studied. Several oxidative stress biomarkers in blood and follicular fluid will be also measured for these women, who will complete a questionnaire on their lifestyles. Finally, thanks to in vitro approaches, the effects and the mechanisms of action (including oxidative stress) of these pollutants (alone or in cocktails) will be studied on granulosa cells from these patients.
After being informed about the project Fertenox during a meeting describing about the Fecondation In Vitro protocol, all women patients not opposing to participate in the study and to use individual information will be included in the research during the usual bacteriological exam performed 1-2 months before oocyte pick up in the University hospital. They will receive the questionnaire on their lifestyle during this exam.
On the eve of the oocyte pick up (at the end of ovarian stimulation) during the usual blood collection, three additional tubes of blood will be collected for each patient in the University hospital. Women will also receive the screw-top container for morning-after urine sample and the completion of the lifestyle questionnaire will be checked (some advices will be done if necessary to help patients to fill out the questionnaire). Samples will be treated, aliquoted and stored according to requirements the same day.
The day of the oocyte pick up, the first morning urine will be collected by patients at home (or otherwise in the hospital). The completed questionnaire will be recovered and follicular fluid and granulosa cells will be collected for each woman. Samples will be aliquoted and stored according to requirements the same day. Granulosa cells will be cultured for in vitro approaches in research labs the same day.
Tubes of blood, urine and follicular fluid will be coded and kept at -80°C in the University hospital until their shipment to laboratories, where analyses of pollutants (bisphenols, ethynylestradiol and glyphosate) and analyses of oxidative stress biomarkers (antioxidant vitamins, FRAP), activity of several enzymes (catalase, superoxide dismutase, glutathione peroxidase) and oxidized lipids) will be performed.
Women followed in the department for an in vitro fertilisation procedure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women followed in the department for an in vitro fertilisation protocol
Other: Blood sample · Other: Urine sample · Other: Follicular fluid and granulosa cells sample
Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
Collection of the first urine in the morning on the day of the oocyte pick-up
Collection of follicular fluid and granulosa cells during oocyte pick-up.
Presence or absence of ethinylestradiol in follicular fluid
Assessed by measure of ethinylestradiol in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Presence or absence of ethinylestradiol in urine
Assessed by measure of ethinylestradiol in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Presence or absence of bisphenols in follicular fluid
Assessed by measure of bisphenols in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Presence or absence of bisphenols in urine
Assessed by measure of bisphenols in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: Baseline
Presence or absence of glyphosate in follicular fluid
Assessed by measure of glyphosate in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Presence or absence of glyphosate in urine
Assessed by measure of glyphosate in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Concentration of ethinylestradiol in follicular fluid
Assessed by concentration of ethinylestradiol in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Concentration of ethinylestradiol in urine
Assessed by concentration of ethinylestradiol in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Concentration of bisphenols in follicular fluid
Assessed by concentration of bisphenols in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Concentration of bisphenols in urine
Assessed by concentration of bisphenols in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Concentration of glyphosate in follicular fluid
Assessed by concentration of glyphosate in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Concentration of glyphosate in urine
Assessed by concentration of glyphosate in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)
Time frame: baseline
Oocyte quality
Assessed by nuclear maturity of each collected punctured oocyte
Time frame: baseline
Embryo quality
Assessed by in vitro early embryo developmental competence of each punctured oocyte (Day 2 embryo morphology, ability to reach the blastocyst stage, Day 5/6 blastocyst morphology, blastocyst outcome (transfer, freezing, discarding)
Time frame: Day 2 and day 5/6 after oocyte pick up
Embryo implantation success (pregnancy success)
Assessed by confirmation of a clinical pregnancy (blood beta human chorionic gonadotropin assay: \> 1000 Unity Intenational /L), by confirmation of on-going pregnancy (ultrasound measure of foetus cardiac activity) and by confirmation delivery of live and healthy birth
Time frame: From day 7 after embryo transfer for beta hCG assay, at 8 weeks of amenorrhea for foetus cardiac activity and after birth
Oxidative stress biomarkers in follicular fluid
Assessed by measure of antioxidant vitamins (carotenoids, vitamin E, retinol) by High Performance Liquid Chromatography
Time frame: baseline
Oxidative stress biomarkers in follicular fluid
Assessed by measure of oxidized lipids (isoprostanoids) by LC-MS/MS
Time frame: Baseline
Oxidative stress biomarkers in follicular fluid
Assessed by measure of antioxidant power (FRAP: Ferric ion Reducing Antioxidant Power) by spectrophotometry
Time frame: Baseline
Oxidative stress biomarkers in follicular fluid
Assessed by measure of glutathione peroxidase activity by spectrophometry
Time frame: Baseline
Oxidative stress biomarkers in blood
Assessed by measure of plasma antioxidant vitamins (carotenoids, vitamin E, retinol) by HPLC
Time frame: On the eve of baseline
Oxidative stress biomarkers in blood
Assessed by measure of plasma oxidized lipids (isoprostanoids) by LC-MS/M
Time frame: On the eve of baseline
Oxidative stress biomarkers in blood
Assessed by measure of plasma antioxidant power (FRAP) by spectrophotometry
Time frame: On the eve of baseline
Oxidative stress biomarkers in blood
Assessed by measure of activities of glutathione peroxidase, catalase and superoxide dismutase in red blood cells by UV and visible spectrophometry
Time frame: On the eve of baseline
Oxidative stress biomarkers in urine
Assessed by measure of oxidized lipids (isoprostanoids) by LC-MS/MS
Time frame: baseline
Information on woman lifestyles
Assessed by a questionnaire on sociodemographic characteristics, smoking, physical activity, professional and environmental expositions, consumption of dietary supplements (antioxidants), consumption of drinks (tap water, from plastic bottle, cans...), food reheating habit, consumption of food from tin box, use of hygiene and cosmetic products...
Time frame: The 3 last months of lifestyles before baseline
Pollutant effects on patient granulosa cells in vitro
Assessed on cellular viability (CCK8, live-dead assay)
Time frame: after 24 or 48h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on proliferation (BrdU)
Time frame: after 24 or 48h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on steroid production (ELISA, LC-MS)
Time frame: after 48 or 72h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on energetic metabolism (mitochondrial and glycolytic activities by Seahorse and Omnilog assays)
Time frame: after 1 or 24h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on oxidative stress biomarkers (reactive oxygen production, Nrf2 nuclear translocation by confocal microscopy, cytometry and fluorimetry)
Time frame: after 5, 6 or 24h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on protein expression (Western Blotting) of several markers of the studied functions (including oxidative stress)
Time frame: after 24, 48 or 72h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on gene expression (RNAseq and Quantitative Reverse Transcription-PCR) of several markers of the studied functions (including oxidative stress)
Time frame: after 6 or 24h of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on protein expression (Western Blotting ) of signaling pathways
Time frame: after 1, 5, 10, 30 and 60 min of exposure
Pollutant effects on patient granulosa cells in vitro
Assessed on gene expression (RNAseq and qRT-PCR) of signaling pathways
Time frame: after 6h of exposure
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's planned 60 months is above that.
Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.